In a nutshell This study investigated the safety and effectiveness of MOR208 in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma. This study concluded that MOR208 monotherapy was safe and showed promising results in these patients. Some background Chemoimmunotherapy is the current standard first-line...
Read MoreIn a nutshell This article reviewed the results of new targeted immunotherapy treatments in patients with classical Hodgkin’s lymphoma that is relapsed or refractory (does not respond to treatment). Some background Thanks to treatment advances, classical Hodgkin’s lymphoma (cHL) has become one of the most curable cancers. Frontline ABVD...
Read More
In a nutshell This study investigated the outcomes of advanced-stage classical Hodgkin’s lymphoma (HL) patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by escalated (higher dose) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) chemotherapy...
Read More
In a nutshell This study looked at the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) to treat patients with relapsed or difficult to treat Hodgkin lymphoma. The study concluded that the combination of brentuximab vedotin and nivolumab is an effective treatment for patients with relapsed Hodgkin lymphoma. Some...
Read More
In a nutshell This phase 2 trial aims to test the effectiveness of a combined treatment with Brentuximab vedotin (Adcetris) in patients 60 years of age or more with Hodgkin lymphoma. The main outcome to be measured will be tumor response to the treatment and side effects. This trial is recruiting throughout the United States. The details...
Read More
In a nutshell This study aimed to investigate if a treatment combination including brentuximab vedotin (Adcetris) would be effective in treating patients with advanced Hodgkin’s lymphoma. This study concluded that treatment combinations with and without brentuximab vedotin were effective but one (BrECADD) was associated with fewer side...
Read More
In a nutshell The aim of this trial is to determine how patients with advanced, hormone-resistant prostate cancer with evidence of a homologous recombination gene deficiency respond to rucaparib (Rubraca) treatment. The main outcome to be measured is the response to treatment, and changes to prostate-specific antigen levels (a protein present in...
Read More
In a nutshell This study investigated the negative side effects of targeted therapy to treat elderly and younger metastatic (spread to other parts of the body) colorectal cancer patients. Researchers suggested that side effects were different between these patients. Some background Colorectal cancer is one of the most common cancers worldwide....
Read More
In a nutshell This study examined the effectiveness of FOLFOXIRI combined with targeted therapy (TT) in advanced colorectal cancer. This study concluded that FOLFOXIRI plus TT was associated with better outcomes compared to other treatment combinations. Some background Chemotherapy is used to reduce symptoms and increase survival in colorectal...
Read More
Video information: Are there new developments in treating metastatic lung cancer? Dr. David Carbone of Ohio State University Comprehensive Cancer Center has much to report. From new medications that directly impact quality of life, rapid research to patients who are outliving their original prognosis, Dr. Carbone weighs in on...
Read More
In a nutshell This study examined the safety and effectiveness of durvalumab (Imfinzi) in patients with stage III non-small cell lung cancer. This study concluded that durvalumab delayed time to disease progression. Some background Chemotherapy and radiation are the standard treatment options for stage III non-small cell lung cancer (NSCLC, cancer...
Read MoreIn a nutshell This study aimed to compare the pathological complete response (pCR) rates of two neoadjuvant therapy combinations for HER2 positive (HER2+, dependent on HER2 for growth) breast cancer. This study concluded that the combination of pertuzumab (Perjeta), trastuzumab (Herceptin) and chemotherapy resulted in higher pCR rates than...
Read More
